This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Implied Volatility Surging for Diplomat Pharmacy (DPLO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Diplomat Pharmacy (DPLO) stock based on the movements in the options market lately.
Company News for Nov 29, 2019
by Zacks Equity Research
Companies In The News Are: CENT, BOX, DPLO, EVH
Diplomat Pharmaceuticals (DPLO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Diplomat Pharmaceuticals (DPLO) delivered earnings and revenue surprises of -40.00% and 11.81%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Diplomat Pharmaceuticals (DPLO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Diplomat Pharmaceuticals (DPLO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rite Aid (RAD) Incurs Loss in Q1, Revenues Decline Y/Y
by Zacks Equity Research
Rite Aid (RAD) incurs loss in first-quarter fiscal 2020. However, it reaffirms outlook for the fiscal year.
New Strong Sell Stocks for May 10th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Diplomat Pharmaceuticals (DPLO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Diplomat Pharmaceuticals (DPLO) delivered earnings and revenue surprises of -371.43% and 8.43%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Diplomat Pharmaceuticals (DPLO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Diplomat Pharmaceuticals (DPLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Diplomat Pharmacy (DPLO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Diplomat Pharmacy (DPLO) stock based on the movements in the options market lately.
Diplomat Pharmaceuticals (DPLO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Diplomat Pharmaceuticals (DPLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for November 27th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Diplomat Pharmaceuticals (DPLO) Reports Break-Even Earnings for Q3
by Zacks Equity Research
Diplomat Pharmaceuticals (DPLO) delivered earnings and revenue surprises of -100.00% and -4.69%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Diplomat Pharmaceuticals (DPLO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Diplomat Pharmaceuticals (DPLO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Diplomat Pharmaceuticals (DPLO) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Diplomat Pharmaceuticals (DPLO) delivered earnings and revenue surprises of -26.09% and -0.33%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
3 Staples ETFs & Stocks to Buy on Retail Sales & Geopolitics
by Sanghamitra Saha
Why these consumer staples ETFs and stocks are rallying in recent trading.
Top Ranked Momentum Stocks to Buy for February 2nd
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, February 2nd:
Top Ranked Momentum Stocks to Buy for February 1st
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 1st:
Top Ranked Momentum Stocks to Buy for January 24th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 24th:
Rite Aid (RAD) on Track with Asset Sale: Is it Aiding Stock?
by Zacks Equity Research
Rite Aid Corporation (RAD) is on track with the process of transferring stores and related assets to Walgreens under its amended and restated asset purchase agreement.
Zacks.com highlights: Rice Midstream Partners, Jacobs Engineering Group, Lam Research, Diplomat Pharmacy and Forward Air
by Zacks Equity Research
Zacks.com highlights: Rice Midstream Partners, Jacobs Engineering Group, Lam Research, Diplomat Pharmacy and Forward Air
5 Low Leverage Stocks to Buy Amid Rate Hike Woes
by Zacks Equity Research
Since huge debt tends to shoot up the company's risk of bankruptcy, the crux of safe investment lies in identifying low leverage stocks.
Rite Aid (RAD) Soars Too High Too Fast: Is This Justified?
by Zacks Equity Research
Rite Aid Corporation (RAD) stock seems to have gained solid momentum following the recent sale of stores to Walgreens. However, the company has been facing issues with dismal sales, heavy debt burden and strained margins.
Rite Aid (RAD) Q3 Earnings Beat, Stores Transfer on Track
by Zacks Equity Research
Rite Aid Corporation (RAD) reported third-quarter fiscal 2018 results, which marked a considerable improvement from the company's recent trend. Further, it continues to transfer stores to Walgreens.
GNC Holdings (GNC) Looks Good: Stock Adds 10.2% in Session
by Zacks Equity Research
GNC Holdings (GNC) shares rose more than 10% in the last trading session, amid huge volumes.
Can Diplomat Pharmacy (DPLO) Keep the Earnings Streak Alive This Quarter?
by Zacks Equity Research
Diplomat Pharmacy (DPLO) can be a harbinger of out performance and a signal for a strong earnings profile on the back of its favorable Zacks rank and earnings ESP in the positive territory.